title: Pathology and Neurotoxicity in Dogs after Repeat Dose Exposure to a Serotonin 5-HT1B Inhibitor.
abstract: AZD3783, a cationic amphiphilic drug and a potent inhibitor of the 5-hydroxytryptamine (5-HT1B) receptor, was explored as a potential treatment for depression. To support clinical trials, repeat dose toxicity studies in rats and dogs were conducted. Here we report toxicity findings in dogs after dosing from 1 to 3 months. In the 1-month study, there were minimal neuronal vacuolation in the brain, a marked increase in liver enzymes accompanied by hepatocellular degeneration/necrosis and phospholipidosis (PLD), and PLD/cholecystitis in the gallbladder of animals dosed at 47 mg/kg/day. In the 3-month study, neurotoxicity resulted in euthanasia of one animal dosed at 30 mg/kg/day after 86 days. Extensive pathologic changes were seen in all animals in retina epithelium (inclusion bodies), brain (neuronal vacuolation, degeneration, or necrosis and nerve fiber degeneration), spinal ganglia (vacuolation, degeneration, or necrosis), as well as sciatic and optic nerves (degeneration). Pigment-laden macrophages were observed in the lung, kidney, liver, gallbladder, bone marrow, gastrointestinal tract, and lymphoid tissues. Also seen were vitrel and retinal hemorrhage in the eyes. A brain concentration and pathology study showed that the concentration of AZD3783 in the brain was approximately 4 times higher than in the plasma after 4 weeks of dosing, however, they were similar in all regions examined, and did not correlate with areas with pathologic findings. Our findings with AZD3783 in dogs have not been reported previously with other CNS compounds that effect through serotonergic pharmacology.
authors.affiliation: AstraZeneca R&D, Wilmington, DE 19850, USA.
authors.forename: Jane C F
authors.initials: JC
authors.lastname: Chang
authors.affiliation: AstraZeneca R&D, Wilmington, DE 19850, USA ; Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Ciaccio
authors.affiliation: AstraZeneca R&D, Wilmington, DE 19850, USA ; EMD Serono, 45 A Middlesex Turnpike, Billerica, MA 01821, USA.
authors.forename: Patricia
authors.initials: P
authors.lastname: Schroeder
authors.affiliation: AstraZeneca R&D, Alderly Park, Macclesfield, Cheshire SK10 4TG, England.
authors.forename: Lindsay
authors.initials: L
authors.lastname: Wright
authors.affiliation: AstraZeneca R&D, Alderly Park, Macclesfield, Cheshire SK10 4TG, England.
authors.forename: Russell
authors.initials: R
authors.lastname: Westwood
authors.affiliation: AstraZeneca R&D, Södertälje, Sweden ; MPA, Läkemedelsverket, Uppsala, Sweden.
authors.forename: Anna-Lena
authors.initials: AL
authors.lastname: Berg
keywords: dog; pathology; neurotoxicity; preclinical safety assessment; phospholipidosis; cationic amphiphilic drugs (CADs)